EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Factors related to the development of high antibody titres against SARS‐CoV‐2 in convalescent plasma donors from the ConPlas‐19 trial

Irene Romera Martínez, Cristina Avendaño-Solá, Carolina Villegas Da Ros, Alba Bosch Llobet, José Antonio García Erce, María Isabel González Fraile, Luisa Guerra Domínguez, Isabel Vicuña Andrés, Javier Anguita Velasco, Victoria Paz González Rodríguez, Enric Contreras, Sabin Urcelay Uranga und 9 weitere

Vox Sanguinis · 2024

DOI: 10.1111/vox.13561 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Vox Sanguinis, 2024. Verfasst von Irene Romera Martínez und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Hospital Universitario Puerta de Hierro Majadahonda, Instituto de Investigación Sanitaria Hospital Puerta de Hierro-Segovia…. Hauptthemen laut MEDLINE: COVID-19, SARS-CoV-2. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: European Regional Development Fund (FEDER), Government of Spain, Ministry of Science and Innovation, Instituto de Salud Carlos III, SCReN (Spanish Clinical Research Network), Instituto de Salud Carlos III.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Objectives The efficacy of COVID‐19 convalescent plasma (CP) associates with high titres of antibodies. ConPlas‐19 clinical trial showed that CP reduces the risk of progression to severe COVID‐19 at 28 days. Here, we aim to study ConPlas‐19 donors and characteristics that associate with high anti‐SARS‐CoV‐2 antibody levels. Materials and Methods Four‐hundred donors were enrolled in ConPlas‐19. The presence and titres of anti‐SARS‐CoV‐2 antibodies were evaluated by EUROIMMUN anti‐SARS‐CoV‐2 S1 IgG ELISA.

Results

A majority of 80.3% of ConPlas‐19 donor candidates had positive EUROIMMUN test results (ratio ≥1.1), and of these, 51.4% had high antibody titres (ratio ≥3.5). Antibody levels decline over time, but nevertheless, out of 37 donors tested for an intended second CP donation, over 90% were still EUROIMMUN positive, and nearly 75% of those with high titres maintained high titres in the second sample. Donors with a greater probability of developing high titres of anti‐SARS‐CoV‐2 antibodies include those older than 40 years of age (RR 2.06; 95% CI 1.24–3.42), with more than 7 days of COVID‐19 symptoms (RR 1.89; 95% CI 1.05–3.43) and collected within 4 months from infection (RR 2.61; 95% CI 1.16–5.90). Male donors had a trend towards higher titres compared with women (RR 1.67; 95% CI 0.91–3.06).

Conclusion

SARS‐CoV‐2 CP candidate donors' age, duration of COVID‐19 symptoms and time from infection to donation associate with the collection of CP with high antibody levels. Beyond COVID‐19, these data are relevant to inform decisions to optimize the CP donor selection process in potential future outbreaks.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19SARS-CoV-2FemaleHumansMaleAntibodies, NeutralizingAntibodies, ViralBlood DonorsCOVID-19 SerotherapyImmunization, PassiveImmunoglobulin GClinical Trials as Topic

Stichwörter der Autor:innen

COVID-19anti-SARS-CoV-2convalescent plasmadonorspassive immunotherapy

Substanzen

Antibodies, NeutralizingAntibodies, ViralImmunoglobulin G

Autor:innen und Institutionen

  • Department of Hematology, Hospital Universitario Puerta de Hierro Majadahonda, Instituto de Investigación Sanitaria Hospital Puerta de Hierro-Segovia de Arana, Madrid, Spain.
  • Department of Clinical Pharmacology, Hospital Universitario Puerta de Hierro Majadahonda, Instituto de Investigación Sanitaria Hospital Puerta de Hierro-Segovia de Arana, Madrid, Spain.
  • Department of Hematology, Hospital Universitario 12 de Octubre, Madrid, Spain.
  • Banc de Sang i Teixits de Catalunya, Barcelona, Spain.
  • Banco de Sangre y Tejidos de Navarra, Servicio Navarro de Salud, Osasunbidea, Pamplona, Spain.
  • Grupo Español de Rehabilitación Multimodal (GERM), Instituto Aragonés de Ciencias de la Salud, Zaragoza, Spain.

ORCID-Profile: Teresa Jimenez-Marco, Rafael F Duarte

Förderung

  • European Regional Development Fund (FEDER)
  • Government of Spain, Ministry of Science and Innovation, Instituto de Salud Carlos III
  • SCReN (Spanish Clinical Research Network), Instituto de Salud Carlos III
  • Spanish Clinical Research Network

Zitieren

APA

Romera Martínez, I., Avendaño-Solá, C., Villegas Da Ros, C., Bosch Llobet, A., García Erce, J. A., González Fraile, M. I., Guerra Domínguez, L., Vicuña Andrés, I., Anguita Velasco, J., González Rodríguez, V. P., Contreras, E., Urcelay Uranga, S., Pajares Herraiz, Á. L., Jimenez-Marco, T., Ojea Pérez, A. M., Arroyo Rodríguez, J. L., Pérez-Olmeda, M., Ramos-Martínez, A., Velasco-Iglesias, A., …, & Duarte, R. F. (2024). Factors related to the development of high antibody titres against SARS‐CoV‐2 in convalescent plasma donors from the ConPlas‐19 trial. Vox Sanguinis. https://doi.org/10.1111/vox.13561

Vancouver

Romera Martínez I, Avendaño-Solá C, Villegas Da Ros C, Bosch Llobet A, García Erce JA, González Fraile MI, et al. Factors related to the development of high antibody titres against SARS‐CoV‐2 in convalescent plasma donors from the ConPlas‐19 trial. Vox Sanguinis. 2024. doi:10.1111/vox.13561

BibTeX
@article{RomeraMartnez2024,
  author = {Romera Martínez, Irene and Avendaño-Solá, Cristina and Villegas Da Ros, Carolina and Bosch Llobet, Alba and García Erce, José Antonio and González Fraile, María Isabel and Guerra Domínguez, Luisa and Vicuña Andrés, Isabel and Anguita Velasco, Javier and González Rodríguez, Victoria Paz and Contreras, Enric and Urcelay Uranga, Sabin and Pajares Herraiz, Ángel Luis and Jimenez-Marco, Teresa and Ojea Pérez, Ana María and Arroyo Rodríguez, José Luis and Pérez-Olmeda, Mayte and Ramos-Martínez, Antonio and Velasco-Iglesias, Ana and Bueno Cabrera, José Luis and Duarte, Rafael F},
  title = {Factors related to the development of high antibody titres against SARS‐CoV‐2 in convalescent plasma donors from the ConPlas‐19 trial},
  journal = {Vox Sanguinis},
  year = {2024},
  doi = {10.1111/vox.13561}
}
Kostenlos starten →